FTC litigator: agency eyes REMS abuse as pay-for-delay wanes

As fewer drugmakers cut reverse-payment deals, the Federal Trade Commission is keeping a close eye on pharmaceutical companies that abuse safety protocols to prevent competition, one of the agency’s top litigators has said.

Unlock unlimited access to all Global Competition Review content